Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Current nucleic acid amplification methods to detect Mycobacterium tuberculosis are complex, labor-intensive, and technically challenging. We developed and performed the first analysis of the Cepheid Gene Xpert System's MTB/RIF assay, an integrated hands-free sputum-processing and real-time PCR system with rapid on-demand, near-patient technology, to simultaneously detect M. tuberculosis and rifampin resistance. Analytic tests of M. tuberculosis DNA demonstrated a limit of detection (LOD) of 4.5 genomes per reaction. Studies using sputum spiked with known numbers of M. tuberculosis CFU predicted a clinical LOD of 131 CFU/ml. Killing studies showed that the assay's buffer decreased M. tuberculosis viability by at least 8 logs, substantially reducing biohazards. Tests of 23 different commonly occurring rifampin resistance mutations demonstrated that all 23 (100%) would be identified as rifampin resistant. An analysis of 20 nontuberculosis mycobacteria species confirmed high assay specificity. A small clinical validation study of 107 clinical sputum samples from suspected tuberculosis cases in Vietnam detected 29/29 (100%) smear-positive culture-positive cases and 33/39 (84.6%) or 38/53 (71.7%) smear-negative culture-positive cases, as determined by growth on solid medium or on both solid and liquid media, respectively. M. tuberculosis was not detected in 25/25 (100%) of the culture-negative samples. A study of 64 smear-positive culture-positive sputa from retreatment tuberculosis cases in Uganda detected 63/64 (98.4%) culture-positive cases and 9/9 (100%) cases of rifampin resistance. Rifampin resistance was excluded in 54/55 (98.2%) susceptible cases. Specificity rose to 100% after correcting for a conventional susceptibility test error. In conclusion, this highly sensitive and simple-to-use system can detect M. tuberculosis directly from sputum in less than 2 h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have shown that Xpert does not cross‐react with other mycobacterial species (Blakemore 2010; Helb 2010).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Helb 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This represents a substantial reduction in diagnostic delay, thereby permitting real-time decision making and planning of treatment (5).”
From Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens (2011) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies reported 98–100% agreement in detection of rifampicin resistance strains using the Xpert test and phenotypic drug susceptibility test [13,14,18,26].”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Such cases (Xpert-positive but culture-negative) are likely to be true TB positives as corroborated by the high specificity [14,18] and by the fact that the procedure is less prone to contamination due to the closed reaction chamber (real-time PCR technology) of Xpert.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In agreement with other studies [9,18,22], Xpert has a higher sensitivity than smear microscopy.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
Probable Inference, the Law of Succession, and Statistical Inference
Wilson, E. B. (1927) · Journal of the American Statistical Association · doi:10.1080/01621459.1927.10502953 · Cited by 4,476
Sexually transmitted diseases treatment guidelines
Burstein, G. R., & Workowski, K. A. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200308000-00006 · Cited by 2,072
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
Workowski, K. A., & Berman, S. M. (2007) · Clinical Infectious Diseases · doi:10.1086/511430 · Cited by 1,973
The association for the advancement of medical instrumentation
(1974) · Ultrasound in Medicine & Biology · doi:10.1016/0301-5629(74)90035-0 · Cited by 1,031
Anti-tuberculosis drug resistance in the world
Wilkinson, D. (1998) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(98)90766-0 · Cited by 700
Molecular Detection of Antimicrobial Resistance
Fluit, A. C., Visser, M. R., & Schmitz, F.-J. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.836-871.2001 · Cited by 525 · cited 1×
“tuberculosis detection (15), this assay was too complex and too prone to operator errors, sample cross-contamination, and biohazards for rapid near-patient use.”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 3×
“Truly rapid results for drug susceptibility tests are particularly important in the management of drug-resistant tuberculosis (13).”
BackgroundMicroscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB
Moore, D. A. J., Evans, C. A. W., Gilman, R. H., Caviedes, L., Coronel, J., Vivar, A., Sanchez, E., Piñedo, Y., Saravia, J. C., Salazar, C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055524 · Cited by 468
Cited by
Items 701–800 of 940
3.29 Nanomaterials for Biological Sensing
Herpoldt, K., Loynachan, C. N., & Stevens, M. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803581-8.09301-2 · Cited by 4
Review on convectional and advanced diagnostic techniques of human tuberculosis
Tadesse, B., & Eyasu, E. (2015) · Journal of Medical Laboratory and Diagnosis · doi:10.5897/jmld2012.0101 · Cited by 3
“It is an automated molecular test for the diagnosis of MTC infections and the identification of antimicrobial multi-resistance using sputum samples (Helb et al., 2010).”
MethodRakha, E., & Elshahawy, H. A. (2018) · Comparative Clinical Pathology · doi:10.1007/s00580-017-2631-z · Cited by 3
“In agreement with our results, different studies carried out in different countries revealed a sensitivity and specificity ranging from 94 to 100% (Saeed et al. 2017; Pandey et al. 2017; Tang et al. 2017; Narute et al. 2015; Zetola et al. 2014; and Helb et al. 2010).”
ResultPrevalence of Nontuberculous Mycobacteria: A Single Center Study in Tehran, Iran
Nasiri, M. J., Feizabadi, M. M., Dabiri, H., & Fooladi, A. A. I. (2018) · Archives of Clinical Infectious Diseases · doi:10.5812/archcid.61042 · Cited by 3
Talip, B. A., Snelling, W. J., Sleator, R. D., Lowery, C. J., & Dooley, J. S. G. (2018) · BMC Microbiology · doi:10.1186/s12866-018-1335-0 · Cited by 3
Velasco, J. M., Gaurano, N., Valderama, M. T., Nogrado, K. S., Diones, P. C., Lopez, M. N. B., Liao, C., Chua, D., Develos, M., Fernandez, S., et al. (2020) · Military Medicine · doi:10.1093/milmed/usz456 · Cited by 3
Gogoi, S., Bora, I., Debnath, E. M., Sarkar, S., Jais, M. B., & Sharma, A. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1793_20 · Cited by 3
“CBNAAT FOR SARS –COV 2: Principle: This automated system is also based on the basic principle of rRT‐PCR to detect SARS‐COV2, but it integrates the various steps like the sample preparation, viral RNA extraction, amplification as well as detection of target sequences in a single cartiridge.[24,25] It uses single‐time…”
MethodAbaate, T. J., & Alali, A. (2023) · medRxiv · doi:10.1101/2023.02.21.22282624 · Cited by 3
Metabolic control of drug resistance by a mycobacterial ion channelPreprint
Gouzy, A., Li, S., Chen, J., Na, A., Saleh, A. M., Azadian, Z. A., Tam, K., Munsamy, V., Poulton, N. C., DeJesus, M. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.10.710584 · Cited by 3
“However, pncA is dispensable for bacterial fitness, resulting in a diffuse mutational landscape 16,18 that complicates the development of targeted molecular diagnostics analogous to those used to detect rifampicin-resistance 19 .”
Nguyen, T. B. N., Nguyen, T. K. D., Phan, V. B. T., Tran, T. T. N., Phan, V. B. T., Nguyen, T. T., Nguyễn, H. B., Ngo, V. Q. T., Mai, V. T., & Molicotti, P. (2023) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2023.0124 · Cited by 2
“In contrast, molecular assays offer faster results without compromising sensitivity and specificity [24,25].”
BackgroundNelson, D. J., Chugh, K., Pua, H. H., & Haselton, F. R. (2025) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.12.007 · Cited by 2
Rahman, S. M. M., Ruhee, N. N., Haider, A., Hasan, M. J., Nasrin, R., Adel, A. S. S., Uddin, M. K. M., Ahmed, S., Maug, A. K. J., & Banu, S. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01127-0 · Cited by 2
“The Xpert MTB/RIF (Xpert) and Xpert MTB/RIF Ultra (Xpert Ultra) assays (Cepheid, CA, USA), endorsed by the WHO, are molecular tests that can rapidly detect TB and provide drug resistance information for only rifampicin (RIF) within 2 h [5, 6].”
Su, B., Qi, H., Tan, Y., & Huang, H. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002009 · Cited by 2
“The LOD of the Xpert assay is reported as 131 AFB ml −1 , with a turnaround time of about 2 h [20].”
Singh, S., & Shrivas, A. (2025) · The Indian Journal of Medical Research · doi:10.25259/ijmr_527_2025 · Cited by 2
“To overcome this challenge M/s Cepheid Inc. (USA) and Foundation for Innovative New Diagnostics (FIND), with financial support from the ‘National Institutes of Health (NIH), USA’, modified the technology and first time applied and evaluated for the diagnosis of TB on clinical samples in 2010 30 .”
Yang, Z., Ma, Z., Liu, Z., Li, P., Liu, Y., Cai, L., Su, B., Li, D., Wang, L. L., Cui, L., et al. (2026) · Journal of Clinical Microbiology · doi:10.1128/jcm.01433-25 · Cited by 2
“For the Xpert MTB/RIF assay, 1.0 mL of raw sample was mixed with 2.0 mL of sample reagent according to the manufacturer’s instructions (17).”
InfluentialAhamed, M. A., Guo, B., Khalid, M. A. U., Pal, T., Guo, F., & Guan, W. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103033 · Cited by 2
Rudra, P., Parmar, H., Daivaa, N., Tran, C., Narang, A., Singh, S., Somaiya, D., Roybardhan, S., Anwesa, R., Reiss, R., et al. (2026) · Journal of Clinical Microbiology · doi:10.1128/jcm.01100-25 · Cited by 4
“…each sample (sputum or buffer A containing Tris, EDTA, and tween, spiked with known numbers of M. tuberculosis CFU, clinical sputum sample, or cultured bacterial suspension) was mixed at a 2:1 ratio with sample reagent (SR) and incubated at room temperature for 15 min with occasional shaking (46).”
Self-citationAlmutairi, M., Alalmaee, R., Alamer, E., Alharbi, S., Aljarallah, G. S., Almukhayzim, R., Albuhayjan, N., & Abanamy, R. (2026) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2026.100603 · Cited by 2
“[12,25] In line with this, Mekkaoui et al. observed that Xpert-Ultra false-negative results were associated with a low bacterial burden, as reflected by a prolonged time-to-culture positivity [26].”
Savić, M., Theron, G., Bobosha, K., Nyombi, B., Laake, I., Josifoski, A., Arsov, J., Assefa, T., Bikombo, J., Borain, N., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103914 · Cited by 2
Ray, A., Suri, J. C., Sen, M. K., Chakrabarti, S., Gupta, A., & Capoor, M. R. (2015) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2015.02.009 · Cited by 2
Bemba, E. L. P., Okombi, F. H. O., Bopaka, R. G., & Abacka, K. B. O. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/j.rmra.2019.11.612 · Cited by 2
Wang, H.-Y., Ahn, K., Uh, Y., Lee, H., Kim, S., Chang, Y., Chang, C. L., & Shim, T. S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01804 · Cited by 2
“4%) were detected and 9/9 (100%) were RIF resistant as revealed by Xpert MTB/RIF assay (Helb et al., 2010).”
BackgroundMethodNg, B. Y. C., Wee, E. J. H., West, N. P., & Trau, M. (2019) · Wiley eBooks · doi:10.1002/9781119282686.ch33 · Cited by 2
Sumayya, S., Durga, K., S, N. B., Fatima, S., & Krishnaiah, A. (2019) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2019/765 · Cited by 2
Conventional and Modern Approaches for Clinical and Laboratory Diagnosis of Tuberculosis
Sharma, M. K., Wonitowy, Q., & Soualhine, H. (2022) · Springer eBooks · doi:10.1007/978-981-16-8845-4_10 · Cited by 3
Amjad, A., Yousuf, Z., & Muzammil, H. S. (2021) · Futuristic Biotechnology · doi:10.54393/fbt.v1i01.6 · Cited by 2
Goyani, K. H., & Mukhopadhyaya, P. N. (2023) · Archives of Infectious Diseases & Therapy · doi:10.33140/aidt.07.03.01 · Cited by 2
Advances in the Diagnosis of HIV-Associated Tuberculosis
Gupta‐Wright, A., & Lawn, S. D. (2015) · EMJ Respiratory · doi:10.33590/emjrespir/10313482 · Cited by 5
Rapid diagnosis of tuberculosis in a peripheral setting
Pienaar, E. (2010) · Lincoln (University of Nebraska) · Cited by 2
Ileocaecal tuberculosis: re‐emergence in developed countries
Choy, M. C., Christensen, B., & Desmond, P. V. (2013) · Internal Medicine Journal · doi:10.1111/imj.12056 · Cited by 2
Xpert MTB/RIF: The newly endorsed TB diagnostic
Nikam, C., & Rodrigues, C. S. (2014) · Pediatric Infectious Disease · doi:10.1016/j.pid.2014.07.003 · Cited by 2
PERFORMANCE AND BIOSAFETY IMPLICATIONS OF GENEXPERT MTB/RIF ASSAY.
Nwokoye, N., Onubogu, C. C., At, A., Ck, O., Gidado, M., Elom, E., & Oe, I. (2014) · Cited by 2
Tuberculose: le réveil d’une belle endormie
Blanc, F. –. (2011) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(11)70165-3 · Cited by 2
Point-of-Care Diagnostics for Tuberculosis: Are we there?
Mansour, A. B. (2013) · Mycobacterial Diseases · doi:10.4172/2161-1068.1000e124 · Cited by 2
Point-of-Care Technologies for the Diagnosis of Active Tuberculosis
(2016) · Molecular Microbiology · doi:10.1128/9781555819071.ch40 · Cited by 2
Palomino, J. C., & Martin, A. (2015) · Wiley eBooks · doi:10.1002/9781118644843.ch45 · Cited by 3
Abdelhaleem, A. A., Hershan, A. A., & Agarwal, P. K. (2017) · Journal of Tuberculosis Research · doi:10.4236/jtr.2017.51001 · Cited by 2
Porter, B. W., & Venkatappa, T. K. (2018) · Tuberculosis · doi:10.1016/j.tube.2018.08.014 · Cited by 2
Noussair, L., Bert, F., Leflon‐Guibout, V., Métivier, R., Chauvet, C., Napol, C., & Nicolas-Chanoine, M.-H. (2018) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2018.11.004 · Cited by 2
Bonney, W., Price, S. F., & Miramontes, R. (2019) · PubMed · Cited by 2
Nshizirungu, L., Olet, D., Amulen, D., Oming, M., Luwuna, P., & Wewedru, I. (2020) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v1i12.7 · Cited by 2
Predictores de tuberculosis pulmonar y experiencia con su diagnóstico molecular rápido
Outeda, M., Marchissio, E., Gadea, P., Labadie, I., Bica, A., & Seija, V. (2021) · Revista Médica del Uruguay · doi:10.29193/rmu.37.1.5 · Cited by 2
“Este hecho llamó la atención, ya que diferentes series demuestran una disminución de sensibilidad de esta prueba en muestras con baciloscopía negativa((9-11)).”
BackgroundChallenges in Drug Discovery against Tuberculosis
Dwivedi, M., & Giri, P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97857 · Cited by 4
Machowski, E. E., Letutu, M., Lebina, L., Waja, Z., Msandiwa, R., Milovanovic, M., Gordhan, B. G., Otwombe, K. N., Friedrich, S. O., Chaisson, R. E., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06133-4 · Cited by 3
Technical and Clinical Niches for Point-of-Care Molecular Devices
Hansen, G. T., & Baron, E. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-95111-9_10 · Cited by 3
Epidemiology of Molecular Probes in Xpert MTB/RIF Assay in AJK, Pakistan
Baber, J. Z., Ali, I., Qasim, Z., Saba, N., Akram, S., Nouman, M., Waheed, U., & Wazeer, A. (2023) · Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University · doi:10.48036/apims.v19i2.519 · Cited by 2
Sharma, R., ., V., Yadav, D., Kaliraman, V., & Duhan, A. (2024) · Cureus · doi:10.7759/cureus.64332 · Cited by 2
“For sputum samples, it has shown a sensitivity of 81% and a high specificity of 98%, as demonstrated in early studies on patients with pulmonary TB [10].”
BackgroundPersonalized Approach as a Basis for the Future Diagnosis of Tuberculosis (Literature Review)
Хромова, П. А., Sinkov, V. V., & Савилов, Е. Д. (2019) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2019-4.3.17 · Cited by 2
Molecular Basis of Drug Resistance in Mycobacterium tuberculosis
Cohen, K. A., Bishai, W. R., & Pym, A. S. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch21 · Cited by 3
Gupta, R. K. (2023) · Indian Journal of Respiratory Care · doi:10.5005/jp-journals-11010-1004 · Cited by 1
Kaur, J., Jain, A., & Rai, A. K. (2024) · Indian Journal of Otolaryngology and Head & Neck Surgery · doi:10.1007/s12070-024-04786-6 · Cited by 2
“GeneXpert MTB/ RIF assay is not user-dependent and gives results in less than two hours [25].”
Doungous, D. M. (2024) · Journal of Clinical Medical Research · doi:10.46889/jcmr.2024.5208 · Cited by 1
Wang, Z., Zou, Y., Wei, Z., Bai, G., Wang, X., Qu, S., Shi, J., Jiang, Y., & Gu, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1534268 · Cited by 1
Tenorio, B. G., Uayan, D. J. F., Lumunsad, K. F., Estuart, A. S., Javier, J. C. R., & Abad, C. L. R. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.117008 · Cited by 1
Soni, A., Mishra, R., Nath, A., & Kapoor, P. (2025) · Cureus · doi:10.7759/cureus.91825 · Cited by 4
“With results available in under two hours and minimal technical requirements, this assay has been widely adopted in national TB programs, especially in decentralized settings [4,5].”
Wei, S., Yong, Z., Lin, J., Lin, S., Dai, Z., Lin, Y., & Deng, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-40398-6 · Cited by 1
Muchahary, J., Nongpiur, V. N., Lyngdoh, W. V., Kalita, P., Marbaniang, E., Raphael, V., Gogoi, N., & Lohe, Y. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3811 · Cited by 1
Uddin, M. K. M., Kabir, S. N., Rupa, A. A., Ferdous, J., Nasrin, R., Islam, A., Nashra, A., Rahman, S. M. M., Sikder, A. A., & Banu, S. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103271 · Cited by 1
Ma, Z., Yu, X., Yu, Y., Wang, Y., Shi, J., Jing, W., Shang, Y., Ren, W., Li, H., Zhang, T., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag342 · Cited by 1
The many facets of drug susceptibility testing for Mycobacterium tuberculosis
Baron, E. J. (2013) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2013.08.004 · Cited by 1
Munir, M. K., Rehman, S. U., Iqbal, R., & Saeed, M. (2016) · Annals of King Edward Medical University · doi:10.21649/akemu.v21i4.779 · Cited by 1
“S.(4) Chairman Dept of TB and Chest Medicine KEMU / Mayo Hospital, Lahore Xpert MTB / RIF assay simultaneously detects the presence of MTB, and its susceptibility to the important first – line drug rifampicin.”
BackgroundMethodJudicious application of controls as a cost-effective approach to routine diagnostic PCR testing
McIver, C. J., Er, N., Hanrahan, J. R., & Siebert, D. J. (2015) · Pathology · doi:10.1097/pat.0000000000000306 · Cited by 1
Comparison of GeneXpert MTB/RIF Assay in Broncho Alveolar Lavage and Gastric Lavage Samples
Mahat, R., Rizvi, N. A., Saifullah, N., Tawfik, M., & Kumar, A. (2016) · Advances in Infectious Diseases · doi:10.4236/aid.2016.63014 · Cited by 1
“Previous studies of the GeneXpert that assessed either sputum samples or concentrated decontaminated sputum pellets, have shown test sensitivity of 72% - 75% in cases of smear-negative tuberculosis and 98% - 100% in cases of smear-positive tuberculosis and specificity 99% [11]-[15].”
Collantes, J., Barletta, F., & Rigouts, L. (2016) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-0120 · Cited by 1
Rapid Molecular Detection of Tuberculosis and Rifampicine Resistance in Ecuador
Pardón, F., Andrade, S., Campañá, L., Jinez, H. E. J., Barberán, J., Valdés, Y., Narváez, A., & Cajas-Flores, N. V. (2017) · Advances in Infectious Diseases · doi:10.4236/aid.2017.74013 · Cited by 1
“This value is similar to the resistance values described in previous studies in Ecuador between 2008 and 2009 [14].”
MethodResultInfluentialEFFICACY OF CB-NAAT IN DETECTING SPUTUM NEGATIVE PULMONARY TUBERCULOSIS
Mohan Rao, K. N., Vinod, K., Ishwarappagol, P., Gundappa, V., Noorullah, M. P., & Farhat, N. (2017) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2017/1030 · Cited by 1
Isolated tubercular parapharyngeal abscess masquerading as peritonsillar abscess: A case report
Patel, S., Kumar, R., Sagar, P., & Kumar, R. (2018) · Otolaryngology Case Reports · doi:10.1016/j.xocr.2018.02.003 · Cited by 1
Obioma, A., Ngozika, W. G., & Appollus, J. N. (2018) · Journal of Microbiology & Experimentation · doi:10.15406/jmen.2018.06.00195 · Cited by 1
Mosquera-Restrepo, S. F., Villanueva, M. C. M., & López, M. R. (2017) · Medicina y Laboratorio · doi:10.36384/01232576.4 · Cited by 1
Chen, Z., Jiang, H., Tan, Y., Kudinha, T., Cui, J., Zheng, L., Cai, C., Li, W., & Zhuo, C. (2019) · Radiology of Infectious Diseases · doi:10.1016/j.jrid.2020.02.002 · Cited by 1
Chin, K. L., Sarmiento, M. E., Mustapha, Z. A., Jani, J., Jamal, N. B., Stanis, C. S., & Acosta, A. (2020) · Tuberculosis · doi:10.1016/j.tube.2020.102003 · Cited by 1
Clinical Interpretation of Drug Susceptibility Tests in Tuberculosis
Laniado-Laborín, R. (2020) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x16999201007164411 · Cited by 1
High-Throughput Variant Detection Using a Color-Mixing Strategy
Xie, N. G., Zhang, K., Song, P., Li, R., Luo, J., & Zhang, D. Y. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.04.015 · Cited by 1
Çavuşoğlu, C., & SOYLU, M. (2015) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2014.061 · Cited by 1
Abdulmajed, O., Koç, A. N., Gültekin, A., & Atalay, M. A. (2015) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2013.130 · Cited by 1
Garg, P. K., Yagnik, V. D., & Dawka, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9053-2_9 · Cited by 1
Sharma, R., Garasiya, K., & Meena, R. L. (2022) · Indian Journal Of Applied Research · doi:10.36106/ijar/8503959 · Cited by 1
Zhurilo, A. A., Барбова, А. І., Cherednik, Y. A., Trofimova, P. S., Mironchenko, S. V., Pavlova, O. V., Chernov, A. V., & Sladkova, L. M. (2022) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2022-30-4-34-41 · Cited by 1
Guan, Z., Han, X., Huang, W., Wang, X., Wang, H., & Fan, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1128337 · Cited by 1
Mycobacterium tuberculosis Tanısında İki Farklı Gerçek Zamanlı PCR Yönteminin Değerlendirilmesi
Timur, D., Parkan, Ö. M., Kılıç, H., Atalay, M. A., Tekinsen, F. F., & Koç, A. N. (2023) · Medical Research Reports · doi:10.55517/mrr.1215658 · Cited by 1
Role of GeneXpert in extrapulmonary tuberculosis
Azzouz, A. M., El-Sokkary, R. T. I., Wafi, L. S., & Khalaf, M. G. A. (2023) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.4103/ecdt.ecdt_114_22 · Cited by 1
Yadav, K. R., & Shrestha, K. (2024) · Birat Journal of Health Sciences · doi:10.62065/bjhs476 · Cited by 1
“19,20 We found relatively fewer cases of RIF resistance 17(23.94”
BackgroundInfluentialHigh-volume biological sample processing using microwaves
Wilson-Garner, S., Alzeer, S., Baillie, L. W. J., & Porch, A. (2024) · Journal of Applied Physics · doi:10.1063/5.0178755 · Cited by 1
Farnia, P., Ghanavi, J., Aghajani, J., Ayoubi, S., Besharati, S., Farnia, P., & Velayati, A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21712-8.00018-1 · Cited by 1
Mining Work and Health Problems in the Eastern Region of Morocco
Bekkaye, K. E., & -, O. Q. (2024) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2024.v06i05.27567 · Cited by 1
“The GenXpert MTB/RIF Test is a system that can detect MTB DNA and mutations that confer resistance to RIF in less than two hours (Helb et al ., 2010).”
MethodClinical Management of Drug-Resistant Tuberculosis in Resource Constrained Settings
Palmero, D., & Ritacco, V. (2013) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6560 · Cited by 1
Lemus-Minor, C. G., Ovalle-Marroquín, D. F., Vázquez-Jiménez, J. G., Reales-Agüero, D. L., Sepulveda-Alcantara, P. M., Sánchez, J. R., Díaz-Molina, R. J., & Machado-Contreras, J. R. (2018) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2018.07.002 · Cited by 1
ROLE OF MOLECULAR DIAGNOSTIC TEST IN DIAGNOSING PULMONARY AND EXTRAPULMONARY TUBERCULOSIS
Mathew, S., Pradhani Manjunath, M., & Philomina, B. (2018) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2018/627 · Cited by 1
Laboratory diagnosis of tuberculosis
Tagliani, E., Nikolayevskyy, V., Tortoli, E., & Cirillo, D. M. (2018) · European Respiratory Society eBooks · doi:10.1183/2312508x.10021318 · Cited by 3
Klinische Anwendungen von mikrobiologischen Schnelltests
Stürenburg, E. (2008) · Springer eBooks · doi:10.1007/978-3-540-79152-2_32 · Cited by 1
“[35] Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K et al.”
BackgroundRosales-Klintz, S. (2010) · Figshare · Cited by 1
GeneXpert: A momentous innovation that needs a touch of prudence
Basil, M. V., & Shah, A. (2017) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2017.02.002 · Cited by 1
Improving point-of-care diagnosis of tuberculosis: development and evaluation of novel technologies
Moodley, V. M. (2017) · Open University of Cape Town (University of Cape Town) · Cited by 2
Singh, V. K. (2014) · Unisa Institutional Repository (University of South Africa) · Cited by 1
Do no harm - re-evaluating the risks of overtreatment in community-wide tuberculosis screeningPreprint
Houben, R. M. G. J., Veeken, L. D., Schwalb, A., Grint, D. J., Wasserman, S. A., van Crevel, R., & Horton, K. C. (2025) · medRxiv · doi:10.1101/2025.09.18.25335917 · Cited by 3
“However, sputum culture is imperfect, as illustrated by the fact that with repeated cultures more individuals test positive at least once (14,15).”
Molecular epidemiology of Mycobacterium tuberculosis and antibiotic resistance in Lao PDR
Somphavong, S. (2018) · theses.fr (ABES) · doi:10.70675/712e0d40zc7f9z4428z894bz6270c6ac0df2 · Cited by 1
“tuberculosis is identified when at least two of the five probes give positive signals with a cycle threshold (CT) of ≤38 cycles [111, 112].”
BackgroundGonzalez, R. M. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Interaction between Mycobacterium tuberculosis and pulmonary epithelium.
Ashiru, O. T. (2013) · ResearchSpace (University of KwaZulu-Natal)
Times have Changed! The Molecular Revolution in TB Diagnostics and Detection of Drug Resistance
Koornhof, H. J., & Coetzee, G. J. (2011) · Southern African Journal of Epidemiology and Infection · doi:10.1080/10158782.2011.11441458
Metadata
- Authors
- Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., Safi, H., Blakemore, R., Lan, N. T. N., Jones-López, E. C., Levi, M., Burday, M., Ayakaka, I., Mugerwa, R. D., McMillan, B., Winn-Deen, E., Christel, L., Dailey, P., Perkins, M. D., Persing, D. H., & Alland, D.
- Affiliations
- Rutgers New Jersey Medical School (US)
- Cepheid (United States) (US)
- Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey
- FIND (CH)
- Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam
- Montefiore Medical Center (US)
- Makerere University (UG)
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 48
- Issue
- 1
- Pages
- 229-237
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC2812290
- OpenAlex
- W2112022845
- Cited by
- 914
- References
- 59
- Citations by year
- 2026: 29 · 2025: 38 · 2024: 35 · 2023: 33 · 2022: 36 · 2021: 45 · 2020: 65 · 2019: 55 · 2018: 61 · 2017: 62 · 2016: 63 · 2015: 62 · 2014: 74 · 2013: 71 · 2012: 62
- FWCI
- 41.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R41AI052523, R42AI052523, R42-AI52523, R41-AI52523)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- Mycobacterium tuberculosis detection, rifampicin resistance, Xpert MTB/RIF, point-of-care testing, real-time PCR, sputum, detection limit, nontuberculous mycobacteria, retreatment tuberculosis, tuberculosis diagnosis
- MeSH terms
- Adolescent, Adult, Aged, Antitubercular Agents, Bacteriological Techniques, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis, Rifampin, Sensitivity and Specificity, Sputum, Tuberculosis, Uganda, Vietnam, Polymerase Chain Reaction, Point-of-Care Systems, Drug Resistance, Bacterial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.